All these encouraging results have led to a priority review of the FDA’s Biologic License Application (BLA) and advance efforts to approve rozanolizizumab for the treatment of adults with generalized MG (gMG) who are AChR or MuSK antibody positive. Here, MUSK is linked to myasthenia gravis.